Cellular stress response pathways and diabetes mellitus

Araki, Eiichi; Kondo, Tatsuya; Kai, Hirofumi

doi:10.1007/s13340-015-0229-8

Cited by 1 publication

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite intensified insulin therapy, the majority of patients with T1D fail to achieve optimal glycaemic control, 4 and even among those who do achieve their HbA1c targets, hypoglycaemia and weight gain associated with intensive insulin use can lead to diminished quality of life 5–7 . According to 2018 statistics from the Japan Diabetes Clinical Data Management Study Group (JDDM), 8 mean HbA1c (a measure of long‐term blood glucose control) in patients with T1D was 7.76%, which is higher than the 7.03% observed in patients with type 2 diabetes (T2D) and exceeds the diabetes treatment target of 7.0% 9 . 10 Although insulin therapy represents life‐saving treatment for patients with T1D, most patients experience treatment‐related hypoglycaemia that affects their daily lives, and severe hypoglycaemia is a life‐threatening risk.…”

Section: Introductionmentioning

confidence: 99%

“…Insulin therapy is also associated with a long‐term risk of weight gain 9 . 10 JDDM statistics show that the mean body mass index (BMI) in Japanese patients has gradually increased from 22.21 kg/m 2 in 2003 to 23.12 kg/m 2 in 2018, 8 although the ideal BMI does not exceed 22 kg/m 2 for both males and females in Japan and obesity is defined as a BMI of 25 kg/m 2 or higher 11 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study

Araki

Mathieu

Shiraiwa³

et al. 2021

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

Aim: To examine the long-term efficacy and safety of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 1 diabetes, in the Japanese subpopulation of the DEPICT-2 study.Materials and Methods: Patients with type 1 diabetes were randomized to dapagliflozin 5 mg (n = 55), dapagliflozin 10 mg (n = 41) or placebo (n = 58) plus insulin for a 24-week, double-blind period followed by a 28-week, single-blind extension phase.Results: From baseline to 24 weeks, dapagliflozin reduced HbA1c compared with placebo (mean change of −0.58% and −0.80% for 5 and 10 mg, respectively), and an HbA1c reduction was observed up to 52 weeks. Compared with placebo, dapagliflozin 5 and 10 mg increased the proportion of patients achieving HbA1c reductions of 0.5% or more without severe hypoglycaemia events and reduced glycaemic variability assessed via continuous glucose monitoring. Both dapagliflozin doses decreased body weight and total daily insulin dose at 24 weeks compared with placebo; these reductions were maintained up to 52 weeks. Diabetic ketoacidosis occurred in both dapagliflozin groups (one and two cases, respectively) but not with placebo.Conclusions: Efficacy and safety results from the Japanese subpopulation of the DEPICT-2 study were generally consistent with those from the overall population, indicating that long-term dapagliflozin adjunct to insulin therapy improves glycaemic control without an increased risk of hypoglycaemia but with a risk of diabetic ketoacidosis in Japanese patients with type 1 diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%